Neuronostics, a Bristol-based startup, has secured funding to accelerate its patented digital biomarker platform for the diagnosis and prognosis of epilepsy [1]. The £3 million funding round was co-led by Empirical Ventures and The FSE Group.
According to Neuronostics, people with suspected epilepsy often wait more than a year before receiving a diagnosis, with misdiagnosis rates potentially exceeding 30 per cent and approximately half of people not being seizure free one year after beginning treatment.
The company’s BioEP platform analyses background EEG activity through eight predefined computational biomarkers to provide objective clinical decision support following an inconclusive EEG. The biomarkers used by the platform are derived from peer-reviewed neuroscience.
The new investment will enable Neuronostics to target three core strategic priorities: broader adoption of BioEP across the NHS; development to provide brain fingerprints of treatment response during pharmaceutical trials; and preparing the company’s FDA submission for the US market.
In addition to co-leads Empirical Ventures and The FSE Group, the round also featured participation from British Business Bank’s South West Investment Fund, QantX, Ascension Ventures, New Wave Venture Partners and Angel Investors Bristol.
The new funding was also bolstered by a £400,000 grant from Innovate UK Investor Partnerships.
John Terry, co-founder and managing director of Neuronostics, commented: “We have the scientific foundation and clinical evidence for BioEP. The quality of the investor syndicate reflects the strength of the commercial opportunity that builds from this.”
“The regulatory path is clear, the partnerships are in place and NHS adoption is building. Patients should not have to wait so long for answers. This is the reason our work matters.”
[1]: Neuronostics Raises £3M to Advance Digital Biomarker Platform